CervoMed Inc (CRVO) Noticias

Form 8-K - Current report

Form 8-K - Current report

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

— Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025...

CervoMed to Present at the 8th International Lewy Body Dementia Conference

BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage...

Form 8-K - Current report

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

—Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary...